(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 May 2013 (23.05.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/072813 A3

(51) **International Patent Classification**:
A61K 47/48 (2006.01) *C07K 7/02* (2006.01)
C07K 5/02 (2006.01)

(21) **International Application Number**:
PCT/IB2012/056224

(22) **International Filing Date**:
7 November 2012 (07.11.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/561,255 17 November 2011 (17.11.2011) US
61/676,423 27 July 2012 (27.07.2012) US

(71) **Applicant**: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) **Inventors**: **DOROSKI, Matthew David**; 52 Church Street, Apartment 2, Mystic, Connecticut 06355 (US). **MADERNA, Andreas**; 54 Pyngyp Road, Stony Point, New York 10980 (US). **O'DONNELL, Christopher John**; 71 Oxford Court, Mystic, Connecticut 06355 (US). **SUBRAMANYAM, Chakrapani**; 314 Great Pond Road, South Glastonbury, Connecticut 06073 (US). **VETELINO, Beth Cooper**; 368 Denison Hill Road, North Stonington, Connecticut 06359 (US). **DUSHIN, Russell George**; 2 Johnny Cake Hill Road, Old Lyme, Connecticut 06371 (US). **STROP, Pavel**; 130 Barneson Avenue #4, San Mateo, California 94402 (US). **GRAZIANI, Edmund, Idris**; 497 South Pascack Road, Chestnut Ridge, NY 10977 (US).

(74) **Agents**: **KLEIMAN, Gabriel, L.** et al.; Pfizer Inc., 235 East 42nd. Street, New York, NY 10017 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report**:
8 August 2013

(54) **Title**: CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF

(57) **Abstract**: The present invention is directed to cytotoxic pentapeptides, to antibody drug conjugates thereof, and to methods for using the same to treat cancer.

WO 2013/072813 A3